The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive ...
With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with ...
News Nation on MSN
Scientists achieve most precise human embryo DNA edit to date
The breakthrough could one day allow doctors to repair disease-causing mutations in embryos.
View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.
Researchers relied on a newer gene-editing technique that may make it possible to engineer embryos, a prospect that has long ...
A team in the US has reported promising results after using an improved form of CRISPR to gene-edit human embryos, but a ...
CRISPR screens generate actionable insights for drug discovery—explore how to optimize a screen, how to avoid pitfalls, and ...
CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results